Becton Dickinson and Company (BDX)

NYSE: BDX · USD

$195

-0.21 (-0.1%)· Recorded snapshot

英語版にフォールバックJA

翻訳中のため英語版を表示しています

このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

StockMarketAgent Research · Analyzed 2026-10-02

Our latest published analysis: BDX rated Hold

Becton Dickinson and Company's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$195 / share

Potential value

$324 / share

Upside to FV

+10.1%

from $195

Moat

7.2/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$48.2B
Revenue (ttm)	22.5B
Net income (ttm)	942M
EPS (ttm)	$3.33
Shares out	272.4M
P/E (trailing)	58.5x
P/E (forward)	13.7x
Dividend	$4.20 (2.16%)
Volume	1,351,015
Beta	0.28

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 22.5B
Net income (ttm): 942M
EPS (ttm): $3.33
P/E (trailing): 58.5x
P/E (forward): 13.7x
Market cap: $48.2B

Item	P1	P2	P3	P4	P5	Trend
Period	2022-09-30	2023-09-30	2024-09-30	2025-09-30	2026-09-30	Trend
Revenue	$18.87B	$19.37B	$20.18B	$21.84B	—	+5.0%
Gross profit	$8.48B	$8.17B	$9.13B	$9.92B	—	+5.4%
Operating income	$2.28B	$2.11B	$2.40B	$2.58B	—	+4.2%
Net income	$1.78B	$1.48B	$1.71B	$1.68B	—	-1.9%
EPS (diluted)	$4.62	$3.88	$4.61	$4.58	$9.04	+18.3%
EBITDA	$4.41B	$4.40B	$4.82B	$4.96B	—	+4.0%
R&D	$1.26B	$1.24B	$1.19B	$1.27B	—	+0.2%
SG&A	$4.71B	$4.72B	$4.86B	$5.28B	—	+3.9%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	売り
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	縮小
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	ホールド
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	縮小
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	強い買い
AMGN	Amgen Inc.	244.2B	28.1x	6.4x	19.8%	+8.4%	+58.6%	買い

Base and Bull scenarios

Base55%

Price target

$194.59

+10.1% from spot

The Base scenario envisions steady hospital procedure replenishment supporting core Medical and Interventional consumable franchises. Operational execution through productivity programs counterbalances selective group purchasing pricing concessions, while international markets compound at moderate single-digit rates. With the shares trading at $176.80 against our Fair value of $194.59, this outcome carries a target of $194.59 at an assigned probability of 55.0%, implying an expected return of 10.1%. Disconfirmation would emerge if core consumable volume growth turns negative or if operating margins slip below targeted levels within the next fiscal year.

Steady procedural replenishment in core hospital medical consumables
Operational productivity initiatives counterbalance hospital pricing pressures
Consistent international revenue expansion across Europe and Asia
Free cash flow prioritized for scheduled debt deleveraging and dividend distributions

Bull20%

Price target

$323.86

+83.2% from spot

The Bull scenario reflects sustained market share capture from competitor supply disruptions, accelerating Medical segment volume growth alongside expanding international adoption. Manufacturing automation and operating leverage widen operating margins toward peer benchmark levels, driving accelerated free cash flow that substantially expedites debt retirement. This upside path yields a target of $323.86 with an assigned probability of 20.0%, representing a return of 83.2% toward Potential value of $323.86. Disconfirmation would occur if competitor capacity quickly restores customer volume share or if hospital capital spending slows within the next two fiscal years.

Accelerated hospital consumable market share capture following competitor outages
Operating margin expansion driven by manufacturing scale efficiencies
Rapid free cash flow generation accelerating balance sheet deleveraging
Re-rating of equity multiple closer to diversified healthcare peer medians

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($194.59). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.7%	2.0%	2.2%	2.5%	2.7%
6.2%	$210	$215	$221	$229	$237
6.7%	$198	$202	$206	$212	$218
7.2%	$188	$191	$195	$199	$203
7.7%	$179	$182	$185	$188	$192
8.2%	$172	$174	$177	$179	$182

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E13.7

P25 n/aP50 n/aP75 n/a

Trailing P/E31

P25 n/aP50 n/aP75 n/a

ROE6.6

P25 n/aP50 n/aP75 n/a

ROIC7.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BDX indicators

Market & fundamental data

Available fields

284

Groups with data

Currency

USD

Showing 284 of 284 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000010795
Company name	Becton, Dickinson and Company
Country	United States
Country code	US
CUSIP number	075887109
Earnings date	2026-11-05
Earnings time	bmo
Employees	72,000
Employees change	-2,000
Employees growth	-2.7%
Enterprise value	$69.2B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	September
Founded	1897
In index	SP500
Industry	Medical Instruments & Supplies
IPO date	1962-04-23
Is primary listing	Yes
Is SPAC	No
ISIN number	US0758871091
Last 10-K release date	2025-11-25
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	1998-08-21
Last stock split type	Forward
Market cap	$53.1B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$194.82
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	BDX
U.S. state	New Jersey
Website	https://www.bd.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	14.99x
Average P/E ratio (10Y)	65.44x
Average P/E ratio (3Y)	42.8x
Average P/E ratio (5Y)	42.69x
Earnings yield	1.71%
EV/Earnings	73.47x
EV/EBIT	18.87x
EV/EBITDA	11.31x
EV/FCF	26.73x
EV/Sales	3.08x
FCF / EV yield	3.74%
FCF yield	4.88%
Forward EV/Sales	3.54x
Forward P/E	14.71x
Forward P/S	2.71x
Graham number	81.96269
Graham upside	-57.96%
Industry forward P/E	22.69x
Industry P/E	75.18x
Lynch fair value	$16.65
Lynch upside	-91.46%
P/(FCF - SBC) ratio	23.03x
P/(OCF - SBC) ratio	17.36x
P/B ratio	2.18x
P/E ratio	58.49x
P/FCF ratio	20.51x
P/OCF ratio	15.89x
P/S ratio	2.36x
Price/EBITDA ratio	8.68x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	16.31%
EBITDA margin	27.22%
Effective tax rate	12.29%
FCF margin	11.51%
Gross margin	46.94%
Operating margin	16.31%
Pretax margin	8.36%
Profit margin	4.19%
Profit per employee	$13,083
Profitable quarters	1
Profitable years	34
Revenue per employee	$312,278
ROA	4.34%
ROA (5Y)	3.22%
ROCE	8.88%
ROE	6.61%
ROE (5Y)	6.51%
ROIC	7.93%
ROIC (5Y)	6.09%
SBC / revenue	1.26%
Tax / revenue	1.03%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-39.21%
EPS growth (Q)	-31.39%
EPS growth 10Y	-4.43%
EPS growth 3Y	-15.54%
EPS growth 5Y	-12.12%
EPS growth years	0
FCF growth	0.86%
FCF growth (Q)	-44.41%
FCF growth 3Y	14.1%
FCF growth 5Y	-9.32%
Gross profit growth	21.08%
Gross profit growth (Q)	3.58%
Gross profit growth 3Y	7.11%
Gross profit growth 5Y	3.11%
Net income growth	-40.57%
Net income growth (Q)	-34.32%
Net income growth 3Y	-15.87%
Net income growth 5Y	-12.76%
Net income growth years	0
OCF growth	2.96%
OCF growth (Q)	-40.13%
OCF growth 10Y	2.81%
OCF growth 3Y	8.2%
OCF growth 5Y	-8.38%
Operating income growth	29.98%
Operating income growth (Q)	-3.21%
Operating income growth 3Y	13.6%
Operating income growth 5Y	2.7%
Revenue growth	18.49%
Revenue growth (Q)	5.44%
Revenue growth (QoQ)	5.71%
Revenue growth 10Y	6.21%
Revenue growth 3Y	5.69%
Revenue growth 5Y	3.35%
Revenue growth quarters	4
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-753M
Depreciation and amortization	$2.5B
EBIT	$3.7B
EBITDA	$6.1B
EPS	$3.33
FCF per share	$9.50
Financing cash flow	$-2.1B
Free cash flow	$2.6B
Free cash flow minus SBC	$2.3B
Gross profit	$10.6B
Income taxes	$231M
Investing cash flow	$-1.1B
Net borrowing	$-2.2B
Net cash flow	$146M
Net income	$942M
Operating cash flow minus SBC	$3.1B
Operating income	$3.7B
Revenue	$22.5B
Stock-based compensation	$283M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.29
Book value per share	$89.64
Debt / EBITDA	2.66
Debt / equity	0.69
Debt / FCF	6.49
Goodwill	$25.9B
Interest coverage	6.23
Long-term assets	$42.6B
Long-term liabilities	$16.9B
Net cash (debt)	$-16.1B
Net cash / market cap	-30.31%
Net debt / EBITDA	2.63
Net debt / equity	0.66
Net debt / FCF	6.22
Piotroski F-Score	7
Property, plant and equipment	$6.1B
Shareholders' equity	$24.4B
Tangible book value	$-9.5B
Tangible book value per share	$-35.06
Total assets	$50.7B
Total cash	$709M
Total debt	$16.8B
Total liabilities	$26.3B
WACC	5.13%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.43
Current assets	$8.1B
Current liabilities	$9.4B
Current ratio	0.87
Inventory turnover	3.28
Net working capital	$1.3B
Quick ratio	0.33
Working capital	$-1.3B
Working capital turnover	-105.07

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	2.14%
Dividend growth	0.96%
Dividend growth (10Y)	4.75%
Dividend growth (3Y)	4.89%
Dividend growth (5Y)	4.81%
Dividend growth years	54
Dividend payment date	2026-09-30
Dividend payment years	56
Dividend payout frequency	Quarterly
Dividend per share	$4.20
Dividend yield	2.16%
Ex-dividend date	2026-09-09
FCF payout ratio	44.19%
Last dividend	$1.05
Payout ratio	126.09%
Shareholder yield	4.29%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	16.18%
10Y return CAGR	5.91%
10Y total return	77.54%
150-day SMA	$165.28
15Y price change	146.99%
15Y return CAGR	9.98%
15Y total return	316.61%
1D price change	-0.11%
1M price change	5.71%
1M total return	5.71%
1W price change	0.26%
1W total return	0.26%
1Y price change	3.89%
1Y return CAGR	35.53%
1Y total return	35.5%
20-day SMA	$188.86
200-day SMA	$169.77
20Y price change	174.88%
20Y return CAGR	8.44%
20Y total return	405.76%
3M price change	22.27%
3M total return	22.99%
3Y price change	-22.77%
3Y return CAGR	1.48%
3Y total return	4.52%
50-day SMA	$186.16
50-day SMA vs 200-day SMA	50over200
52-week high	$213.08
52-week high date	2026-02-04
52-week low	$140.11
52-week low date	2026-06-22
5Y price change	-20.69%
5Y return CAGR	2.52%
5Y total return	13.24%
6M price change	29.35%
6M total return	31.03%
All-time high	$287.32
All-time high date	2023-07-24
All-time low	$1.27
All-time low date	1974-08-19
Average true range (ATR)	$3.92
Average volume	1.4M
Beta (1Y)	0.41
Beta (2Y)	0.42
Beta (5Y)	0.28
Change from 52-week high	-8.57%
Change from 52-week low	39.05%
Change from all-time high	-32.37%
Change from all-time low	15,163.94%
Change from open	-0.32%
Day's gap	0.21%
Dollar volume	$263.2M
High price	$196.64
Low price	$193.97
Monthly RSI	50.74
Open price	$195.44
Position in 52-week range	31.84%
Premarket change	-0.1%
Premarket close	$195.03
Premarket price	$194.84
Previous close	$195.03
Price vs 150-day SMA	17.57%
Price vs 20-day SMA	2.89%
Price vs 200-day SMA	14.46%
Price vs 50-day SMA	4.38%
Relative volume	0.94
RSI	59.31
Sharpe ratio	1.14
Sharpe ratio (3Y)	0.01
Sharpe ratio (5Y)	0.05
Sortino ratio	2.24
Sortino ratio (3Y)	0.22
Sortino ratio (5Y)	0.3
Volume	1.4M
Weekly RSI	60.97
YTD price change	0.12%
YTD total return	29.89%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	271.7M
Float percentage	99.74%
Shares change (QoQ)	-1.95%
Shares change (YoY)	-2.14%
Shares held by insiders	0.17%
Shares held by institutions	98.3%
Shares outstanding	272.4M
Short % of float	3.6%
Short % of shares	3.59%
Short ratio	5.3 days

Deeper analysis on BDX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this BDX report

What is the latest published BDX stock rating?

Becton Dickinson and Company is shown with Hold in the latest published report, analyzed 2026-10-02. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BDX analysis?

The full latest published report, analyzed 2026-10-02, lives at /stocks/BDX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for BDX?

The latest published report analyzed 2026-10-02 gives BDX a fair value of USD 195 and a potential value of USD 324. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the BDX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-02). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldBDX · Fair value $195+10.1%

Read full analysis →

Becton Dickinson and Company (BDX)

Our latest published analysis: BDX rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · BDX

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All BDX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BDX

Frequently asked questions

レーティング履歴

Category	Score	Reading
Valuation	6.0
Management	6.5
Balance Sheet	4.0
Profitability	5.0
Revenue Growth	6.0
Risk Assessment	6.0
Competitive Moat	7.2
Earnings Quality	6.0
Capital Efficiency	3.5